The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia

Mohamed Elbadry 2* , Ahmed Issam Ali 2 , Eman Saleh 1 , Amal Kamal 1 and Ahmed H. Gabr 2

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common problem in aging males which has a potential impact on patients’ health-related quality of life. In the present prospective study, we evaluated the effect of adding solifenacin to tamsulosin, compared to tamsulosin alone on overactive bladder symptoms scores (OABSS) and patients’ quality of life (QoL) in patients with filling lower urinary tract symptoms due to BPH.

Methods: Patients included in our study were randomly assigned into 2 groups: group 1 included patients with BPH who received tamsulosin alone and group 2 included patients with BPH who received a combination of tamsulosin and solifenacin. Treatment period was 12 weeks in both groups. Quality of life and overactive bladder symptoms score questionnaires were obtained and compared in both groups before and after treatment.

Results: No significant differences were found between both groups before treatment. At the end of treatment period, The QoL score for Group 1 patients was significantly greater than the other group (mean rank was 138.98 in tamsulosin group versus 62.02 in the combination group, \( P \)-value < 0.01). Similarly, OABSS for tamsulosin only group was significantly higher than combined treatment patients (mean rank was 145.03 in tamsulin group versus 55.98 in the combination group, \( P \)-value < 0.01).

Conclusion: Adding solifenacin to tamsulosin was associated with an improvement of QoL and OABSS in patients with irritative urinary symptoms due to BPH when compared with tamsulosin monotherapy.

Keywords: BPH, Tamsulosin, Solifenacin

1 Background

Benign prostatic hyperplasia (BPH) is a common benign disease affecting aging males. BPH can affect patients’ health-related quality of life. Irritative voiding symptoms secondary to BPH can lead to sleep disruption, depression, anxiety, increased falls, and sexual problems [1, 2].

Patients with BPH may be presented by irritative and/or obstructive symptoms. Irritative symptoms are in the form of urinary frequency, urgency, nocturia, and urinary incontinence, while obstructive symptoms can be in the form of hesitancy, intermittency, weak stream, or even urinary retention [3, 4].

Different options of treatment are available to treat BPH like, alpha 1 adrenergic blockers (α1-blockers), 5-α reductase inhibitors (5ARIs) or a combination of the both, anticholinergic agents, β3-adrenoceptor agonists, and phosphodiesterase type-5 inhibitors (PDE5i) which have been investigated by new studies for the treatment of BPH.

Recent studies have reported that the add-on effect of anticholinergic to patients already on α-blockers was associated with significant efficacy and health-related
quality of life benefits over α-blockers monotherapy in men with LUTS/BPE [5–7].

The aim of our prospective study is to evaluate the effect of adding Solifenacin to tamsulosin on the overactive bladder symptoms scores (OABSS) and patients’ quality of life (QoL) in patients with filling lower urinary tract symptoms due to BPH.

1.1 Design
Prospective randomized study.

2 Methods
One hundred and seven patients aged 45 years or older, who were being treated for irritative voiding symptoms due to BPH in our urology outpatient clinic, were included in our prospective study. Patients were randomly assigned into 2 groups using opaque envelop technique. The first group (n = 52) was treated with 0.4 mg tamsulosin capsule once daily, and the other group (n = 55) was treated with 0.4 mg tamsulosin plus 5 mg solifenacin tablet once daily for 12 weeks. We obtained the quality of life questionnaire (Table 1) and overactive bladder symptoms score questionnaire (Table 2) and compared them in both groups before and at the end of treatment.

2.1 Sample size calculation
The sample size was calculated using G* power software version 3.1.9.4 and with test family (t-tests), type of power analysis (A priori: Compute required sample size—given α, power and effect size), input parameters, effect size = 0.64, α error = 0.05, power(1−β) = 0.8, and with assuming allocation ratio N1/N2 = 1 resulting output parameters were sample size for each group 40 patients. This yield a total sample size of 80 patients.

2.2 Statistical analysis
Obtained data were presented as mean ± SD, numbers and percentages. Results were analyzed using Student t test and Chi square test (χ² test). Statistical analysis was

| Table 1 Quality of life due to urinary symptoms questionnaire |
|---------------------------------|
| Terrible | Unhappy | Mostly dissatisfied | Mixed about equally satisfied and dissatisfied | Mostly satisfied | Pleased | Delighted | Quality of life due to urinary symptoms |
| 6       | 5       | 4       | 3       | 2       | 1   | 0       |
|If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?|

| Table 2 Overactive bladder symptom score (OABSS) |
|---------------------------------------------|
| Score | Frequency | Question |
| 0     | ≤ 7       | How many times do you typically urinate from waking in the morning until sleeping at night? |
| 1     | 8–14      | How many times do you typically wake up urinate from sleeping at night until waking in the morning? |
| 2     | ≥ 15      | |
| 0     | 0         | |
| 1     | 1         | |
| 2     | 2         | |
| 3     | ≥ 3       | |
| 0     | Not at all| How often do you have a sudden desire to urinate, which is difficult to defer? |
| 1     | Less than once a week | |
| 2     | Once a week or more | |
| 3     | About once a day | |
| 4     | 2–4 times a day | |
| 5     | 5 times a day or more | |
| 0     | Not at all | How often do you leak urine because you cannot defer the sudden desire to urinate? |
| 1     | Less than once a week | |
| 2     | Once a week or more | |
| 3     | About once a day | |
| 4     | 2–4 times a day | |
| 5     | 5 times a day or more | |
conducted using the IBM SPSS (Version 23, 2015) for Windows statistical package. \( P \)-value < 0.05 was considered statistically significant.

### 3 Results

Out of 52 patients who received 0.4 mg tamsulosin daily, only 48 patients had completed the study period as 3 patients were excluded from the study due to lost follow-up. The mean age of patients in this group was 63.25 ± 5.1 years old (mean ± SD). The quality of life was significantly improved by the administration of 0.4 mg tamsulosin. Significant improvements were observed in OABSS (Table 3). Out of 55 patients who received tamsulosin 0.4 mg plus solifenacin 5 mg daily, only 49 patients had completed the study period as 5 patients were excluded from the study due to lost follow-up. The mean age of patients in this group was 63.4 ± 5.69 years old (mean ± SD). The quality of life was significantly improved by the administration of 0.4 mg tamsulosin plus 5 mg solifenacin. Significant improvements were observed in OABSS (Table 4).

There was no significant difference between the 2 groups before treatment, but the quality of life score for patients after treatment with tamsulosin only is significantly greater than patients after treatment of tamsulosin plus solifenacin at significant level < 0.01 (Table 5). Also there was no significant difference in OABSS between 2 groups before treatment, but OABSS for group 1 was significantly greater than group 2 patients at significant level < 0.01 (Table 6).
4 Discussion

It is well known that the relief of urinary symptoms will improve the patients’ QOL. In our study, group (A) showed improvement in the QOL (question 8 of IPSS), $2.30 \pm 0.50$ after 12 weeks. The mean change in IPSS-QoL score from baseline to endpoint was (2 points). This improvement was statistically significant ($P$ value < 0.001) and also was in agreement with Chapple et al. (2005) observation, (1.3 points; $P=0.0005$) [8, 9].

In our study, group (B) showed improvement in QOL $4.37 \pm 0.485$ to $1.29 \pm 0.498$. This improvement was statistically significant ($P$ value < 0.001) and in agreement with Van Kerrebroeck et al. (2013), who reported that the Change from baseline to endpoint in the QOL due to urinary symptoms with a combination of solifenacin 6 mg plus tamsulosin OCAS 0.4 mg was (1.3 points) (Fig. 1).

Significant improvements in IPSS QoL score were also reported ($P<0.001$). Our study on Egyptian patients showed higher statistically significant differences than that in the NEPTUNE, which is explained by the preference of our patients to the medical treatment rather than other invasive interferences [10, 11].

In present study, combination therapy was associated with significant additional benefits ($P$ value < 0.001) in

Fig. 1 Consort diagram
QOL when compared with monotherapy with tamsulosin 
OCAS 0.4 mg; these result in agreement with van Kerrebrock et al. (2013) who stated significant improvements in 
IPSS QoL score with combination therapy compared with tamsulosin OCAS (P < 0.05) [10].

Regarding overactive bladder symptom score (OABSS), 
in group (B) the combination therapy proved to be an 
effective treatment because of a statistically significant 
difference (P value < 0.001), as OABSS showed significant 
 improvement from a mean ± SD of 11.43 ± 1.458 to 
5.00 ± 1.064 after 3 months; these results were in agree-
ment with Masumori et al. (2010), and Yamaguchi et al. 
(2011) who found also a significant improvement by addi-
tion of solifenacin to tamsulosin as an improvement from 
8.0 ± 2.5 before addition of solifenacin to 4.8 ± 2.6 after 
12 weeks of adding solifenacin [12]. In ASSIST study, 
OABSS also changes from baseline to end of treatment 
which was statistically significant in cases treated with 
tamsulosin 0.4 mg plus solifenacin 5 mg (P value < 0.001) 
[13, 14].

4.1 Study limitations
Our study lacks placebo group, as many patients at the 
beginning of the study (pilot study) refused to participate 
as a control group, and also most of patients were suffer-
ing from LUTS symptoms, so we found it unethical to 
deprive them from definitive treatment. So the decision 
was not to include placebo group at our study.

5 Conclusion
Our study concluded that in a short term of follow-up, 
the combination of solifenacin plus tamsulosin was asso-
ciated with a benefit on QOL and OABSS in patients 
with mainly irritative symptoms due to benign prostatic 
hyperplasia compared to tamsulosin only.

Abbreviations
BPH: benign prostatic hyperplasia; OABSS: overactive bladder symptoms 
scores; QoL: quality of life; α1-blockers: alpha 1 adrenergic blockers; SARI: 5-α 
reductase inhibitors; PDE5i: phosphodiesterase type-5 inhibitors; LUTS: lower 
urinary tract symptoms.

Acknowledgements
Not applicable.

Authors’ contribution
All authors have made a significant contribution to the findings and methods 
in the paper. ME worked on the idea and design. AI shared in the editing. ES 
helped in data collection and analysis. AK shared in the editing. AG contribu-
ted to revision. All authors read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and material
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.

Ethics approval and consent to participate
All procedures performed were in accordance with the ethical standards of the 
ethics committee IRB of Faculty of Medicine, Minia University, approved on 
February 18, 2018. Ethical Approval number: 236/2018. A written consent was 
taken from all participants after sufficient information about the study.

Consent for publication
Not applicable.

Competing interest
No competing interest is declared by any of the authors.

Author details
1 Faculty of Pharmacy, Minia University, Minya, Egypt. 2 Faculty of Medicine, 
Minia University, Minya, Egypt.

Received: 21 February 2020 Accepted: 9 November 2020 
Published online: 11 December 2020

References
1. Unnikrishnan R, Almassi N, Fareed K (2017) Benign prostatic hyperplasia: 
evaluation and medical management in primary care. Cleve Clin J Med 
84(1):53–64
2. Jung JH, MacDonald R, Kim J, Kim MH, Dahm P (2017) Silodosin for the 
treatment of lower urinary tract symptoms in men with benign prostatic 
hyperplasia. Cochrane Database Syst Rev. 11(11):CD012615. https://doi. 
org/10.1002/14651858.CD012615.pub2
3. Gacci M, Carini M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, Maggi 
M, McVary K, Kaplan S, Oelke M (2014) Management of benign prostatic 
hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging 
31(6):425–439
4. Nevêus T, von Gontard A, Hoebekke P, Höjaldrås K, Baurer S, Bover W, 
Jørgensen TM, Rittig S, Walle J, Yeung C-K (2006) The standardization 
of terminology of lower urinary tract function in children and adoles-
cents: report from the Standardisation Committee of the International 
Children’s Continence Society. J Urol 176(1):314–324
5. Sexton CC, Coyne KS, Kopp NZ, Irwin DE, Milsom I, Ayer LB, Tubaro A, 
Chapple CR, Wein AJ (2009) The overlap of storage, voiding and postme-
turbation symptoms and implications for treatment seeking in the USA, UK 
and Sweden: EpilUTS. BJU Int 103(s3):12–23
6. Abrams P, Cardozo L, Fall M, Grifth D, Rosier P, Ulmsten U, van Ker-
rebroeck P, Victor A, Wein A (2002) The standardisation of terminology 
of lower urinary tract function: report from the standardisation sub-
committee of the international continence society. Am J Obstet Gynecol 
187(1):116–126
7. Dimitropoulos K, Gravas S (2015) Solifenacin/tamsulosin fixed-dose 
combination therapy to treat lower urinary tract symptoms in patients 
with benign prostatic hyperplasia. Drug Des Dev Ther 9:1707
8. Chapple CR, Lorenz J, Mortensen R, Pautner H, Reis MO, Schulman 
CC, van der Putten-Stob I (2005) Tamsulosin oral controlled absorption 
system (OCAS) in patients with lower urinary tract symptoms suggestive 
of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a 
phase 2b dose-response study. Eur Urol Suppl 4(2):25–32
9. Lepor H (1998) Phase III multicenter placebo-controlled study of tamsu-
losin in benign prostatic hyperplasia. Urology 51(6):892–900
10. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakan-
man M, Traudtner K, Drake M, N.S. Group (2013) Combination therapy with 
solifenacin and tamsulosin oral controlled absorption system in a single 
tablet for lower urinary tract symptoms in men with benign prostatic hyperplasia. Drug Des Dev Ther 9:1707
11. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, 
Barbalias G (2003) Combination treatment with an α-blocker plus an 
anticholinergic for bladder outlet obstruction: a prospective, randomized, 
controlled study. J Urol 169(6):2253–2256
12. Masumori N, Tsukamoto T, Yanae M, Horita H, Aoki M (2010) The add-on 
effect of solifenacin for patients with remaining overactive bladder after 
treatment with tamsulosin for lower urinary tract symptoms suggestive 
of benign prostatic obstruction. Adv Urol 2010:205251. https://doi. 
org/10.1155/2010/205251
13. Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, Yokoyama O, Seki N, Yoshida M, N. S. Group (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology 78(1):126–133

14. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68(2):318–323

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.